Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.
Company profile
Ticker
ENDP
Exchange
Website
CEO
Paul V. Campanelli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Endo Pharmaceuticals Holdings Inc
SEC CIK
Corporate docs
IRS number
134022871
ENDP stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
18 Jun 19
CT ORDER
Confidential treatment order
27 Jan 17
CT ORDER
Confidential treatment order
5 Jul 16
CT ORDER
Confidential treatment order
31 Mar 14
15-12B
Securities registration termination
10 Mar 14
10-K
2013 FY
Annual report
3 Mar 14
8-K
Entry into a Material Definitive Agreement
3 Mar 14
25-NSE
Exchange delisting
28 Feb 14
8-K
Endo Reports Fourth Quarter and Full Year 2013 Financial Results
28 Feb 14
NO ACT
No action letter
28 Feb 14
Latest ownership filings
SC 13G/A
Endo Health Solutions Inc.
18 Feb 15
SC 13G/A
Endo Health Solutions Inc.
17 Feb 15
SC 13G
Endo Health Solutions Inc.
11 Feb 15
SC 13G/A
Endo Health Solutions Inc.
10 Apr 14
SC 13G
Endo Health Solutions Inc.
14 Feb 14
SC 13G/A
Endo Health Solutions Inc.
14 Feb 14
SC 13G/A
Endo Health Solutions Inc.
14 Feb 14
SC 13G
Endo Health Solutions Inc.
12 Feb 14
SC 13G
Endo Health Solutions Inc.
10 Feb 14
SC 13G/A
Endo Health Solutions Inc.
10 Feb 14
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|